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The Alzheimer’s disease drug development
landscape
Pieter van Bokhoven1* , Arno de Wilde2, Lisa Vermunt3,4 , Prisca S. Leferink1 , Sasja Heetveld1,
Jeffrey Cummings5, Philip Scheltens2,3 and Everard G. B. Vijverberg3

Abstract
Background: Alzheimer’s disease (AD) is a devastating neurodegenerative disease leading to dementia. The field has
made significant progress over the last 15 years. AD diagnosis has shifted from syndromal, based on signs and symptoms, to a biomarker construct based on the pathological hallmarks of the disease: amyloid β deposition, pathologic
tau, and neurodegeneration. Numerous genetic risk factors for sporadic AD have been identified, providing further
insight into the molecular underpinnings of the disease. For the last two decades, however, drug development for
AD has been proven to be particularly challenging. Here, we provide a unique overview of the drug development
landscape for AD. By comparing preclinical and clinical drug development pipelines, we aim to describe trends and
differences regarding target classes and therapeutic modalities in preclinical and clinical development.
Methods: We analyzed proprietary and public databases and company websites for drugs in preclinical development for AD by the pharmaceutical industry and major clinical trial registries for drugs in clinical development for AD.
Drugs were categorized by target class and treatment modality.
Results: We found a higher proportion of preclinical interventions targeting molecular pathways associated with
sporadic AD genetic risk variants, compared to clinical stage interventions. These include apolipoprotein E (ApoE) and
lipids, lysosomal/endosomal targets, and proteostasis. Further, we observed a trend suggesting that more traditional
therapeutic modalities are developed for these novel targets, while more novel treatment modalities such as gene
therapies and enzyme treatments are in development for more traditional targets such as amyloid β and tau. Interestingly, the percentage of amyloid β targeting therapies in preclinical development (19.2%) is even higher than the
percentage in clinical development (10.7%), indicating that diversification away from interventions targeting amyloid-beta has not materialized. Inflammation is the second most popular target class in both preclinical and clinical
development.
Conclusions: Our observations show that the AD drug development pipeline is diversifying in terms of targets
and treatment modalities, while amyloid-targeting therapies remain a prominent avenue of development as well.
To further advance AD drug development, novel companion diagnostics are needed that are directed at disease
mechanisms related to genetic risk factors of AD, both for patient stratification and assessment of therapeutic efficacy
in clinical trials.
Keywords: Alzheimer’s disease, Drug development, Drug targets, Therapy
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Background
Approximately 47 million people worldwide are living
with dementia of which most are affected with a devastating form of a neurodegenerative disorder called
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Alzheimer’s disease [1]. Clinically, AD shows symptoms
of progressive cognitive impairment ultimately leading
to dementia. Patients with AD and their caregivers are
in urgent need of therapeutic interventions that prevent,
halt, slow, or improve the symptoms of AD. To move the
field forward and accomplish this unmet need, a deeper
understanding of the underlying disease mechanisms is
needed, leading to new therapeutic targets that then can
be used in drug development, and therefore, academia,
biopharmaceutical companies, investors, government,
and the patients must work together.
Several important conceptual shifts around AD have
advanced the field significantly, such as moving from the
syndrome, based on signs and symptoms, to a biomarker
diagnosis based on the pathological hallmarks of the
disease: amyloid β (Aβ) deposition, pathologic tau, and
neurodegeneration [2]. Additionally, genetic risk factors
for the sporadic non-familial form of AD are emerging,
providing further insight into the molecular underpinnings of the disease [2]. Both these shifts and insights
resulted in more target classes to investigate for AD drug
development.
However, over the past two decades, AD drug development has been particularly challenging. The failure of
most AD trials to show efficacy has prevented new treatments from reaching the market, with the exception of
the approval of Biogen’s aducanumab by the US Food and
Drug Administration (FDA). The reasons for these failures are manyfold and have been discussed elsewhere [3].
However, despite these failures in the past, the field has
not lost confidence in drug development for AD, as novel
drug development strategies are emerging.
In this review, we aim to provide a unique overview of
the drug development landscape for AD. In particular, by
comparing drugs in preclinical development by biotechnology or pharmaceutical companies to drugs currently
tested in clinical trials, we identify trends regarding target classes and treatment modalities used and discuss
innovations in AD drug development that hopefully
eventually will be tested in clinical trials.

Methods
Selection of drugs
Drugs in preclinical development

We included drugs that are in development by biotechnology or pharmaceutical companies to provide a dataset of the most relevant drugs selected by the industry for
development. To that end, we analyzed proprietary and
public databases for drugs in preclinical development for
AD. All drugs were manually validated by a rater to have
a valid source, such as a pipeline on a company website,
a press release, or a publication, within the last 5 years
(2016–2020). The 5-year time window was set to limit
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the inclusion of programs that are not currently active.
If the only source was a company website, it was left to
the interpretation of the rater whether the website was
up to date, taking the 5-year time window into account.
Patents were not included as a source. If an intervention
was in clinical development for a different indication but
in preclinical development for AD, the intervention was
classified as preclinical. If a drug was renamed, the drug
name was adapted and scored accordingly. All drugs analyzed were labeled by the rater as “verified,” “unverifiable,”
or “to be discussed.” Drugs labeled as “to be discussed”
were further assessed for validity and appropriate scoring
in consensus meetings among six raters.
Drugs in clinical development

The clinical trial registries from the USA (ClinicalTrials.gov), Europe (eudract.ema.europa.eu), Asia (chictr.
org.cn, cris.nih.go.kr, and umin.ac.jp/ctr), and Australia
(anzctr.org.au) were assessed in December 2020 for clinical trials with “Alzheimer’s disease” as the indication.
Although some trials in other countries might have been
missed, most trials in the four major continents where
AD trials take place will be identified, when appropriately
registered. Generally, compliance with the required trial
registration is considered to be high among trial sponsors [4]. All trials of all drugs in phases 1, 2, and 3 were
included; phase 1/2 and phase 2/3 studies are listed as
phase 1 and phase 2 studies, respectively. We included
trials that are recruiting, not yet recruiting, active,
not recruiting, and enrolling by invitation. We did not
include trials listed as completed, suspended, unknown,
withdrawn, or terminated. We did not include trials of
non-pharmacologic therapeutic approaches such as cognitive therapies, caregiver interventions, supplements,
health tech interventions, and medical foods. We did not
include trials of biomarkers. If there were multiple trials ongoing with an intervention, we included only the
trial that was most advanced in development for AD. If
an intervention was in multiple stages of clinical development for AD, we listed only the most advanced stage.
Trial extensions (e.g., open-label or closed label extensions of a completed double-blind phase of a trial) were
defined as “already listed,” and only the original trial was
scored and included in the analysis. Interventions listed
in multiple trial registries were included only once.
Scoring of drugs
Target class

For all drugs, the primary drug target was identified and
classified according to the terminology of the Common
Alzheimer’s and Related Dementias Research Ontology
(CADRO) [5, 6]. CADRO systematizes the pathological
underpinnings of AD that are the current drug targets
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relevant to AD and provides a framework for classifying
treatment mechanisms. The following target classes for
AD are defined in CADRO: amyloid, tau, apolipoprotein
E (ApoE)/lipids/lipoprotein receptors, neurotransmitter
receptors, neurogenesis, inflammation, oxidative stress,
cell death, proteostasis/proteinopathies, metabolism/bioenergetics, vasculature, growth factors/hormones, synaptic plasticity/neuroprotection, epigenetics, gut-brain axis,
circadian rhythm, environmental factors, others, and
unknown. As some drugs did not fall within any of these
classes, the CARDO target classes were complemented
with the following classes: ER stress/cellular stress, lysosomal/endosomal and autophagy, and antiviral/antibacterial. Target classes are defined based on the primary
target of the active ingredient, not on any possible downstream effects. If there were multiple mechanisms of
action, a literature search was performed to establish the
most dominant mechanism or the target class and the
agent was classified as “multitarget.”
Treatment modality

Every drug was classified by the chemical structure of
the active ingredient [7]. Drugs were classified into the
following groups: small molecule, antibody, enzyme/
protein, peptide, DNA, RNA, natural product, drug combination, cell therapy, aptamer, bacteria/probiotic, antibody combination, inorganic, others, and unknown.
For all drugs, the drug target and the sponsor (either
the company name, funding agency, or non-profit organization) were noted. For all drugs in clinical development,
we noted the trial registry or registries in which the drug
is listed, the development stage, and the year of study
start.

Results
By the end of 2020, a total of 441 drugs in development
for the treatment of AD were selected as eligible for scoring, of which 291 (66%) were in the preclinical stage of
development, and 150 drugs (34%) were in clinical stages
of development (Additional file 1, number of drugs in
preclinical and clinical development for AD.xls). These
441 drugs are categorized into 22 target classes and 13
treatment modalities. Most drugs were aimed at Aβ (n =
72), inflammation (n = 56), neurotransmitters and receptors (n = 49), and tau (n = 44).
Target classes: preclinical vs clinical

To allow for comparison of the relative number of drugs
per target class in preclinical development vs clinical
development, Fig. 1 shows the percentage of drugs per
target class in preclinical development among all drugs
in preclinical development and the percentage of drugs
per target class in clinical development among all drugs
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in clinical development. We observed a large difference
between clinical (18%) and preclinical (8%) drugs targeting neurotransmitters and receptors. This class includes
for example cholinesterase inhibitors and a partial
NMDA receptor antagonist, which were among the first
approved drugs for symptomatic treatment for AD.
Relatively more drugs targeting Aβ were found in
preclinical development (19%) as compared to clinical
development (11%). As amyloid is the earliest and best
described pathological hallmark of AD, over the last
two decades, much effort has focused on drug development targeting amyloid. However, although several treatments were able to clear Aβ deposits from the brains of
AD patients, cognitive effects were often ambiguous [8].
Therefore, the need to diversify the AD pipeline in terms
of targets has been championed [9]. While we observed
that the drug development strategy is being diversified,
our data indicate that amyloid-targeting therapies remain
a prominent avenue of development.
Tau, the second pathological hallmark of AD, became
more popular as a drug target a bit later than amyloid,
especially when it became evident that tau accumulation is directly associated with cognitive decline in AD,
where Aβ accumulation is suggested to have an indirect,
tau-mediated association with neurodegeneration and
clinical manifestations of AD [10]. Tau is an increasingly
popular target as demonstrated by the fact that only 5%
of the total drugs in clinical development (8 drugs) target
tau, vs 12% of total drugs in preclinical development (36
drugs).
Targeting pathways involved in (neuro)inflammation
remains a strategy of interest both in preclinical and
clinical development [11]. Inflammation is recognized as
a promising target for treatment development in AD. It
is the second most popular class in both clinical development (13%, 20 drugs) and preclinical development
(together with “tau,” also 12%, 36 drugs).
When considering other targets, a substantial increase
is observed for novel target classes in preclinical development. These include ApoE/lipids/lipoprotein receptors, proteostasis/proteinopathies, lysosomal/endosomal
targets, and autophagy. These are all biological processes
tightly linked to the genetic underpinnings of sporadic
AD [12].
Drugs in development per clinical phase

In a standard drug development pyramid, the number
of drugs decreases from phase 1 to phase 3, because of
safety issues or lack of efficacy. However, in AD, more
drugs are in phase 2 of development compared to phase 1
(Fig. 2). This is likely in part because of the use of repurposed compounds that enter at phase 2 without phase
1 and because phase 1 studies are only several weeks in
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Fig. 1 AD drugs in development, preclinical vs clinical. The number of drugs per target class in preclinical development is shown as a percentage
of all drugs in preclinical development, and the number of drugs per target class in clinical development is shown as a percentage of all drugs in
clinical development

duration while in AD phase 2 studies tend to be much
longer in order to be able to show a treatment effect on
a biomarker or on cognitive decline [13]. Furthermore,
we found that few interventions go from phase 2 to 3, in
particular for target classes that are not directly linked to
pathology or genetic risk factors, such as metabolism and
bioenergetics, vasculature, and growth factors and hormones. This could be caused by the lack of biomarkers
to show (hints of ) efficacy for these types of drugs. For a
detailed breakdown of drugs in clinical development for
AD, we refer to Cummings et al. [14].
Treatment modalities of AD drugs

The chemical structure of the active ingredient determined the class of treatment modality of the scored
drugs. More novel treatment modalities, such as enzyme/
protein therapy and gene therapy (DNA/RNA), are
mostly in preclinical stages, while small molecules are
in all stages of development (Fig. 3). Interestingly, novel

treatment modalities are usually developed on more traditional targets such as amyloid and tau, while on new
targets, mostly traditional modalities such as small molecules are developed. For amyloid therapies in clinical
development, mostly antibodies are used, while in the
preclinical stage of development, amyloid is targeted
mostly using small molecules. Of note, about half of the
multitarget interventions are cell therapies.

Discussion
By reviewing AD drugs currently in preclinical development, we provide insight into the future clinical development pipeline. Moreover, comparing drugs currently in
preclinical development to drugs in clinical development
provides knowledge into how the landscape is evolving.
Gaps and trends

We observed that amyloid-targeting therapies are
increasingly being developed in the preclinical setting.
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Fig. 2 Number of AD drugs by clinical development stage, stratified by target class. The size of the dotted circles indicates the number of drugs as
reflected in the legend

This is surprising as several treatments in clinical trials
over recent years were able to clear Aβ deposits from the
brains of AD patients while cognitive effects were often
ambiguous [8]. Strategies entailed for example reduction of Aβ peptide production (such as β-site amyloid
precursor protein cleaving enzyme (BACE) inhibitors
and γ-secretase inhibitors) or clearance of Aβ peptides
and Aβ protein aggregates (such as Aβ-directed antibodies). When treating early symptomatic or asymptomatic
patients with BACE inhibitors, cognition worsened [15].
Moreover, funding agencies such as the Alzheimer’s Disease Discovery Foundation, as well as investors such as
the Dementia Discovery Fund, have put policies in place
to promote diversification of AD interventions and therefore diminution of amyloid targeting drugs. A possible
explanation for our data is that many of the amyloid-targeting drugs in the clinic are monoclonal antibodies, and
funders are searching for small molecules with a similar
plaque-reducing effect that are much less costly to produce and easier to administer. The recent FDA approval

of aducanumab might be followed by several more amyloid-directed therapies.
Apart from pathological hallmarks used as drug targets for AD, the genetic architecture of the late-onset
AD (LOAD) is increasingly being elucidated [16], providing additional avenues for drug development. About
30 common susceptibility loci are known to significantly
affect disease risk and rare variants also contribute to
disease risk [17–19]. A substantial number of these risk
genes are expressed on microglia, myeloid cells in the
brain that are involved in the regulation of the immune
response, inflammation, and clearance of protein aggregates and lipoproteins from the interstitial fluid. These
include, for example, the lipoprotein receptor triggering
receptor expressed on myeloid cells 2 (TREM2), which
may influence neurodegeneration, possibly through
clearance of lipoprotein aggregates; CD33 which may
play a role in protein clearance and other neuroinflammatory pathways mediated by microglia; and phospholipase C gamma 2 (PLCG2) regulating inflammatory

van Bokhoven et al. Alzheimer’s Research & Therapy

(2021) 13:186

Page 6 of 9

Fig. 3 AD drugs per target class, stratified by treatment modality

and metabolic responses in microglia [20]. These and
other risk factors have substantiated the significant role
of neuroinflammation and dysregulation of the immune
response play in AD pathology. This is also reflected in
our data of preclinical and clinical drugs in development
targeting inflammatory pathways.
The strongest genetic risk gene for AD remains APOE.
This was the first risk gene identified for LOAD [21], and
APOE genotype affects the risk of familial and early forms
of AD as well. Risk is dose-dependent, with the major risk
variant APOE4 contributing a threefold increase in AD
among E4 heterozygotes and a 15-fold increase in AD
among E4 homozygotes. ApoE protein acts as the major
lipoprotein carrier in the brain. In addition to APOE,
several other LOAD risk genes, such as ATP-binding cassette A7 (ABCA7), TREM2, clusterin (CLU), and sortilin 1 (SORL1), are involved in lipid metabolism. ABCA7
influences AD risk via a reduced ability to transfer cholesterol to ApoE, TREM2 variants affect the uptake of
lipoproteins on microglia cells, CLU (apolipoprotein J)
plays a role in lipid transport, and SORL1 acts as an ApoE

receptor on neuronal cells [22]. Considering the major
role these functional genomic pathways involving lipid
transport and metabolism play in the pathogenesis of
AD [23], the observation that only 2 drugs (1%) in clinical development target these pathways can be considered
a major gap in the AD drug development pipeline. This
trend might change because in preclinical development,
lipid metabolism is increasingly targeted (18 drugs, 6%).
A similar observation was made for drugs targeting
endosomal and lysosomal pathways, with 5 drugs (2%)
in preclinical development and none in clinical development. This can be considered another gap in the pipeline
as multiple risk genes point towards these pathways for
AD drug development. For example, phosphatidylinositol-binding clathrin assembly protein (PICALM)mediated Aβ generation and clearance may influence the
accumulation of Aβ fragments in AD brains [24], bridging integrator 1 (BIN1) internalizes Aβ peptides and
ApoE via the endosomal-lysosomal pathway [25], and
SORL1 directs APP to the endocytic pathways for recycling [22].
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Limitations

In order to identify drugs in preclinical development for
AD, we set out to identify therapeutics that are developed
by biotechnology or pharmaceutical companies. The
goal here is not to provide the most comprehensive list
of all therapeutics in preclinical development for AD, but
instead to provide a dataset of the drugs most relevant
to the industry for development. It should be noted that
some drugs in preclinical development, especially those
funded by governmental agencies are under-represented
in our review; early drug development for the industry is
increasingly performed in academic laboratories [26].
In our selection of drugs in clinical development stages,
all clinical trials were included regardless of the sponsor of the study, whereas the preclinical stage drugs
were limited to treatments in development and financed
at biotech or pharmaceutical companies. Differences
between these stages might therefore relate not only to
chronologic development trends over time, but may also
reflect differences in (strategic) interests from companies vs non-industry investors. For example, financially
less attractive treatment options where limited return
on investments is expected, such as repurposed drugs,
might be pursued by academia and can therefore be
more highly represented in clinical stages. In our dataset, drugs in clinical development include 71 drugs with
an academic or non-industry sponsor. However, when
we exclude these 71 drugs from the analysis (data not
shown), trends and conclusions remain unchanged.

Conclusions
From our data, we conclude that in drug development for
AD, amyloid-targeting therapies are increasingly being
developed in the preclinical setting, neuroinflammatory
targets are prominent in both preclinical and clinical
development, and preclinical AD drugs are increasingly
targeting the molecular pathways associated with sporadic AD genetic risk variants. These observations have
important implications for how the AD drug development landscape will involve in the coming years.
Implications for AD drug development

Once the preclinical therapies reach the clinic, the field
will need to be prepared for the assessment of their efficacy in patients. Biomarkers will need to be available
that can show pharmacodynamic effects and early signs
of efficacy [3]. This will be essential for the selection of
drugs suitable to progress from early clinical development to phase 3 trials. This requires substantial investment in the development of biomarkers. Examples
include the development of fluid biomarkers to measure
lipoprotein levels and lipid metabolism in cerebrospinal
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fluid [27], and markers of endosomal/lysosomal activity. These markers will require clinical validation in AD
cohorts and memory clinics. Also, brain imaging modalities such as positron emission tomography (PET) tracers
quantifying inflammation, lipid metabolism and buildup,
and endosomal/lysosomal capacity will need to be developed. Furthermore, genetic screening of patients for sporadic AD genetic risk variants will need implementation
to allow for stratification of patients to be included in trials, to reduce the heterogeneity of patients and to allow
for more personalized therapy development directed at
the etiology of the disease in subsets of patients.
Future perspectives

Drug development for AD is and will remain a challenge.
The complexity of the disease with respect to the genetic
risk factors, the pathological underpinnings, and the progressive nature requires a multitude of drug development
strategies. The onset of pathological processes far ahead
of the initial symptoms further complicates the intervention strategies as this requires early detection and
therapeutic intervention [28]. Despite these challenges,
substantial progress has been made in recent years. Drug
development shifted from symptomatic interventions to
drugs targeting AD pathology. On June 7, 2021, this culminated in the first FDA approval of a disease-modifying
drug for AD, the fully human anti-amyloid monoclonal
antibody aducanumab. Despite the controversy around
the approval, this is a major step for the field. Discussing the clinical meaningfulness of the two phase 3 trials of aducanumab goes beyond the scope of this paper.
However, we are hopeful a drug approval by the FDA will
be reflected in an increase in the number of preclinical
and clinical intervention studies in AD. As such, our data
reported here may well serve as a baseline for a comparison in the coming years.
The field and AD patients, in particular, will require
drugs that are effective and can halt progression or even
prevent the disease. Drugs targeting functional genetic
pathways leading to AD pathology are arguably best
suited for preventive strategies and early intervention.
Drugs targeting genetic pathways of neuroinflammation
are currently in clinical stages, and we found the emergence of the first treatments in preclinical development
targeting the lipid metabolism and endosomal/lysosomal
pathways. When the AD drug development field continues to invest in the diversification of drug targets and
diagnostics, we are hopeful for the next generation of AD
drugs that will soon enter clinical trials.
Abbreviations
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